146
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma

ORCID Icon, , , , , , , , & ORCID Icon show all
Pages 1849-1859 | Received 12 Sep 2023, Accepted 12 Oct 2023, Published online: 20 Oct 2023

Figures & data

Figure 1 Flow diagram of the patient characterization process.

Figure 1 Flow diagram of the patient characterization process.

Table 1 Baseline Characteristics

Figure 2 Kaplan–Meier curves of overall survival and progression-free survival. (A) Overall survival. (B) Progression-free survival. (C) Overall survival after propensity score matching. (D) Progression-free survival after propensity score matching.

Abbreviations: TTP, transarterial chemoembolization plus tyrosine kinase inhibitors and anti-programmed cell-death-protein-1 agent; HTP, hepatic infusion chemotherapy plus tyrosine kinase inhibitors and anti-programmed cell-death-protein-1 agent.
Figure 2 Kaplan–Meier curves of overall survival and progression-free survival. (A) Overall survival. (B) Progression-free survival. (C) Overall survival after propensity score matching. (D) Progression-free survival after propensity score matching.

Figure 3 Forest plot for survival outcomes.

Abbreviations: TTP, transarterial chemoembolization plus tyrosine kinase inhibitors and anti-programmed cell-death-protein-1 agent; HTP, hepatic infusion chemotherapy plus tyrosine kinase inhibitors and anti-programmed cell-death-protein-1 agent.
Figure 3 Forest plot for survival outcomes.

Table 2 Summary of Best Response

Table 3 Univariate and Multivariate Analysis of Risk Factors for Overall Survival and Progression-Free Survival